Breaking News
January 17, 2018 - Bariatric surgery extends lifespan in obese patients, shows study
January 17, 2018 - Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease
January 17, 2018 - Ewww Moments in the ER: That’s Improbable!
January 17, 2018 - Booze may help or harm the heart, but income matters
January 17, 2018 - Top nutrients needed to boost mood and energy levels on Blue Monday
January 17, 2018 - Scientists develop unique technique to map elasticity of cell components
January 17, 2018 - Obesity surgery reduces the risk of death by half finds new study
January 17, 2018 - Raw Meat Not the Safest Choice for Your Dog or for You
January 17, 2018 - Men who lack HSD17B4 gene may be more susceptible to treatment-resistant prostate cancer
January 17, 2018 - High-Dose Aspirin Preferred for Kawasaki’s
January 17, 2018 - Study suggests risk management approach to combat EMS fatigue
January 17, 2018 - A new therapy against obesity
January 17, 2018 - Doctors warn against holding your nose and closing your mouth to contain a sneeze
January 17, 2018 - Measles outbreak alarms public health officials
January 17, 2018 - FDA Slaps Class Warning on Gadolinium Contrast Agents
January 17, 2018 - Distinct human mutations can alter the effect of medicine
January 17, 2018 - ASIT biotech’s new article presents clinical results of gp
January 17, 2018 - Alternative tobacco use by adolescents associated with greater odds of future cigarette smoking
January 17, 2018 - A High-Salt Diet Produces Dementia In Mice
January 17, 2018 - Scientists provide insights into crucial interaction for DNA repair
January 17, 2018 - Sanofi and Regeneron Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
January 17, 2018 - Morning Break: Pfizer Kills AD/PD Pipeline; Trump Affirms His Mental Health; Humira Pricing Strategy
January 17, 2018 - Researchers see gene influencing performance of sleep-deprived people
January 17, 2018 - Fast food triggers the immune system making it hyperactive
January 17, 2018 - Scientists find increased risk of HIV outbreaks in Ukraine due to war-related migration
January 17, 2018 - New universal flu vaccine moves to clinical trial phase and could be a reality soon
January 17, 2018 - Cocaine de-addiction breakthrough shows promise
January 17, 2018 - FDA Accepts New Drug Application for Seysara (sarecycline) for the Treatment of Moderate to Severe Acne
January 17, 2018 - Robotic Telestenting; BP Cuff Smartwatch; Medicare Bundled Care
January 17, 2018 - New cellular approach found to control progression of chronic kidney disease
January 17, 2018 - Lamprey genes provide clues to repair spinal cord damage, finds study
January 17, 2018 - Tissue-based soft robot could lead to advances in bio-inspired robotics
January 17, 2018 - Mostly the healthy and wealthy Americans use mobile phone apps to track sleep habits
January 17, 2018 - FDA Alert: Varubi (rolapitant) Injectable Emulsion: Health Care Provider Letter
January 16, 2018 - NeuroBreak: Rough Days for Neuroscience Research; Another Migraine Drug Advances
January 16, 2018 - The ‘greatest pandemic in history’ was 100 years ago – but many of us still get the basic facts wrong
January 16, 2018 - Serena Williams Shares Childbirth Ordeal
January 16, 2018 - The Artificial Brain as Doctor
January 16, 2018 - Type 2 diabetes has hepatic origins
January 16, 2018 - Expert discusses how to identify, support individuals with drug or alcohol addiction in workplace
January 16, 2018 - Starting menstruation early increases risk of cardiovascular disease and stroke in later life
January 16, 2018 - CapsoVision receives CE Mark approval for use of CapsoCam Plus System in pediatric patients
January 16, 2018 - Researchers develop new dynamic statistical model to follow gene expressions over time
January 16, 2018 - Alzheimer’s ‘looks like me, it looks like you’
January 16, 2018 - By the Numbers: Physicians’ Economic Impact
January 16, 2018 - Sound Health | NIH News in Health
January 16, 2018 - Modifying baby formula doesn’t prevent type 1 diabetes in children
January 16, 2018 - Energy drinks dangerous for kids
January 16, 2018 - When you need a breast screening, should you get a 3-D mammogram?
January 16, 2018 - Johns Hopkins gets approval to perform HIV positive to HIV positive living donor kidney transplants
January 16, 2018 - The Salk Institute and Indivumed collaborate for cutting-edge cancer research
January 16, 2018 - Study reveals negative long-term effects of heavy cannabis use on brain function and behavior
January 16, 2018 - Many gym-goers injure themselves by pushing harder to be better than friends
January 16, 2018 - Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
January 16, 2018 - Federal Junk Food Tax Feasible, Study Says
January 16, 2018 - Do girls have stronger teeth than boys?
January 16, 2018 - New high-sensitivity blood tests could aid faster diagnosis and treatment for heart attack
January 16, 2018 - How fatal mitochondrial diseases may strike offspring of families with no history of the conditions
January 16, 2018 - TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
January 16, 2018 - Morning Break: Food Pharmacies; Obamacare Sign-ups Dip; Top Pot Studies
January 16, 2018 - Blood pressure declines 14 to 18 years before death
January 16, 2018 - ViLim Ball technology helps reduce uncontrollable shaking hands
January 16, 2018 - Researchers use immune-mimicking biomaterial scaffolds to fast track T cell therapies
January 16, 2018 - In Wisconsin, hopes rise for production of a lifesaving radioactive isotope
January 16, 2018 - Researchers develop software to better predict risk of leakage around aortic stents
January 16, 2018 - Bile acids could directly burn away lipids in the fat depots
January 16, 2018 - Cycling does not negatively impact sexual and urinary health finds study
January 16, 2018 - Severe peer victimization in childhood may contribute to mental health issues in adolescence
January 16, 2018 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
January 16, 2018 - Just How Often Do Patients Turn Post-Surgical Opioids Into a Habit?
January 16, 2018 - Opioid addiction – Genetics Home Reference
January 16, 2018 - Incomplete revascularization in PCI linked to higher mortality
January 16, 2018 - Machine learning algorithm uses brain scans to predict language ability in deaf children
January 16, 2018 - Penn scientists identify new therapeutic target for treatment of melanoma
January 16, 2018 - The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health
January 16, 2018 - Early influenza testing is critical to prevent serious complications
January 16, 2018 - Study Gets to the Core of Back Pain in Runners
January 16, 2018 - Year in Review: Ophthalmology | Medpage Today
January 16, 2018 - ClinicalTrials.gov: Marijuana Use
January 16, 2018 - Researchers create novel compound targeting melanoma cells
Oral Insulin No Help for T1D Delay or Prevention

Oral Insulin No Help for T1D Delay or Prevention

image_pdfDownload PDFimage_print

Action Points

  • Oral insulin capsules may not be an effective method for preventing type 1 diabetes in relatives of those with type 1 diabetes.
  • Note that there were no serious adverse events, such as severe hypoglycemic events reported during the trial.

Oral insulin capsules may not be an effective method for preventing type 1 diabetes, according to Diabetes TrialNet researchers.

Oral insulin treatment in relatives of those with type 1 diabetes who were positive for at least two autoantibodies did not have a significant effect on time to diabetes compared with placebo (28.5% insulin group versus 33% placebo, HR 0.87, 95% CI 0.0-1.2, P=0.21), reported Jeffrey P. Krischer, PhD, of the University of South Florida College of Medicine in Tampa, and colleagues in the Type 1 Diabetes TrialNet Oral Insulin Study Group, in the Journal of the American Medical Association.

“We now know that we can identify people long before they have clinical type 1 diabetes [T1D]. Indeed, we now consider that having two or more islet autoantibodies is an early stage of type 1 diabetes. Our aim is now to find therapies that can delay or prevent disease progression from early stages to clinically apparent disease,” explained Carla Greenbaum, MD, director of the Diabetes Program at Benaroya Research Institute in Seattle, Washington, to MedPage Today.

“Oral insulin was first tested as part of the Diabetes Prevention Trial (DPT-1), which started in 1994. In that study, a retrospective analysis suggested that those with higher levels of insulin antibodies and thus potentially a more rapid rate of progression to clinical T1D had a benefit [from] oral insulin. These findings led to the launch of the TrialNet Oral Insulin Prevention Study in 2007,” added Greenbaum, who is also chair of Diabetes TrialNet.

The trial included four groups of participants from the TrialNet Natural History Study (now called the TrialNet Pathway to Prevention study), who were all autoantibody-positive relatives of those with type 1 diabetes. The first group — the main focus of the study — included 389 individuals with higher levels of beta cell function. All participants in this group were also positive for microinsulin auto-antibody (mIAA) and either islet cell autoantibodies (ICA) or both glutamic acid decarboxylase (GAD65) antibody and islet antigen 2 (IA-2) autoantibodies.

The participants were randomly assigned to receive a daily 7.5-mg capsule of recombinant human insulin crystals or placebo pills. The groups were followed up every 6 months for a median of 2.7 years.

For the first of the secondary study groups, 55 individuals were included who had the same autoantibody expression as the first group, but had lower levels of beta cell function. This was measured by a first-phase insulin release — marked by adding 1- and 3-minute insulin values form an IV glucose tolerance test — with thresholds lower than 60 μU/mL for those between ages 3 to 7 years, or lower than 100 μU/mL in those age >8 years.

This group experienced a protective effect with oral insulin capsules, marked by a significantly longer time to diabetes in the treatment group versus placebo (HR 0.45, 95% CI 0.0-0.82, P=0.006). After follow-up, only 48.1% of the treatment group progressed to type 1 diabetes compared to 70.3% of placebo.

“It has long been thought that antigen therapy would be most effective earlier in disease. It is somewhat surprising therefore that in both the post-hoc DPT-1 analysis and in TrialNet’s new study, the benefits were seen in groups with potentially more aggressive disease,” Greenbaum noted. “An alternative explanation is that oral insulin is somehow treating an ‘immune flare’ occurring in those most responsive. If true, this may fundamentally change our understanding of mechanisms of disease progression and how we target therapy.”

In a secondary stratum group of 116 individuals who were positive for the mIAA autoantibody and either the GAD or IA-2 autoantibodies. there were no significant differences in the time to diabetes between the groups (HR 1.03, 95% CI 0.0-2.11, P=0.53). Similarly, time to diabetes was not different when they were compared to all groups (HR 0.83, 95% CI 0.0-1.07, P=0.11).

“Since type 1 diabetes is increasingly understood to be a heterogeneous disease it is possible that oral insulin may be helpful in only a subset of people. It is also possible that oral insulin is more helpful at a certain point in time, when insulin-producing cells start to lose function prior to the onset of disease. TrialNet is currently evaluating the results of mechanistic studies to help answer some of those very questions,” Greenbaum added.

There were no serious adverse events, such as severe hypoglycemic events, reported during the trial. Infection was the most commonly reported event, but did not differ between the treatment and placebo groups (134 events treatment versus 120 events placebo).

In terms of future studies, Greenbaum highlighted the “Exploring the Immune Effects of Oral Insulin” study expected early next year, which aims to assess various regimens and dosage levels of oral insulin, and subsequent affect on immune response. “Two other prevention studies also underway are testing the drugs abatacept [Orencia] and teplizumab to see if they can delay or prevent disease progression prior to clinical diagnosis,” she noted.

Greenbaum also encouraged family members of people with type 1 diabetes to be screened for islet autoantibodies through the Pathway to Prevention study.

Click here for the American Association of Clinical Endocrinologists’ clinical practice guidelines for developing a diabetes mellitus comprehensive care plan.

The trial was supported by the Diabetes TrialNet Study Group.

Greenbaum and a co-author disclosed relevant relationships with Eli Lilly.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles